For type 1 Gaucher disease. Sold as Vpriv. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Velaglucerase Alfa (sold as Vpriv), first approved Feb 26, 2010, with 1 new use approved and 0 published complete response letters.
| Vpriv | Part B | $32.3M | -1% | 107 |
| Vpriv | Part D | $9.6M | +3% | 27 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home InfusionGaucher Disease · Takeda | — | Not yet recruiting | Jan 3, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Feb 26, 2010 | VprivBLA 22575 · New molecular entity | Shire Human Genetic | 16 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
